AIM ImmunoTech Inc.
AIM
$0.29
-$0.02-5.79%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -48.24% | -41.05% | -39.80% | -24.35% | -15.84% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -48.24% | -41.05% | -39.80% | -24.35% | -15.84% |
| Cost of Revenue | 312.90% | 163.89% | -39.66% | -34.00% | -26.19% |
| Gross Profit | -128.78% | -88.96% | -39.86% | -20.98% | -13.13% |
| SG&A Expenses | -43.38% | -50.08% | -49.63% | -44.71% | -34.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -41.07% | -47.78% | -47.37% | -46.93% | -37.91% |
| Operating Income | 41.01% | 47.83% | 47.42% | 47.06% | 38.05% |
| Income Before Tax | 19.41% | 34.18% | 42.36% | 51.13% | 40.20% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.41% | 34.18% | 42.36% | 51.13% | 40.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.41% | 34.18% | 42.36% | 51.13% | 40.20% |
| EBIT | 41.01% | 47.83% | 47.42% | 47.06% | 38.05% |
| EBITDA | 41.34% | 48.21% | 47.80% | 47.41% | 38.36% |
| EPS Basic | 61.41% | 58.06% | 56.66% | 61.52% | 47.89% |
| Normalized Basic EPS | 56.40% | 56.43% | 56.24% | 61.36% | 48.56% |
| EPS Diluted | 61.41% | 58.06% | 56.66% | 61.52% | 48.27% |
| Normalized Diluted EPS | 56.40% | 56.43% | 56.24% | 61.36% | 48.56% |
| Average Basic Shares Outstanding | 187.71% | 100.79% | 33.98% | 25.20% | 15.14% |
| Average Diluted Shares Outstanding | 187.71% | 100.79% | 33.98% | 25.20% | 15.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |